| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------|------------------------------------|----------------------|-------|--------------------------|-------|----------------------------------------------------------------------------------------------------------|-------|-----------------------|-----------------|--------------|---------------------------------------------| | | 15% | 12% 00/ | 2% \n740 | | 4% \n29/0 | | | 100% | Rilonacept in RP \ ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -78.57%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced earnings of $0.04, delivering a surprise of 136.36%.Over the last four quarters, the co ...

[Financial & Operational Highlights](index=1&type=section&id=Financial%20%26%20Operational%20Highlights) Kiniksa reported strong Q1 2024 results with significant ARCALYST revenue growth and raised full-year guidance, while advancing pipeline and maintaining positive cash flow expectations ARCALYST Net Product Revenue | Metric | Q1 2024 | YoY Growth | | :--- | :--- | :--- | | ARCALYST Net Product Revenue | $78.9 million | 85% | ARCALYST 2024 Net Product Revenue Guidance | Guidance | Previous Range | Updated Range | | :--- | :--- | :--- | | ARCALYST 2024 Net Product Revenue | $360 - $380 million | $370 - $390 million | - A **Phase 2b trial** for **Abiprubart** in **Sjögren's Disease** is planned to start in the second half of 2024[1](index=1&type=chunk)[7](index=7&type=chunk) - The company expects its current operating plan to maintain a **positive cash flow** on an annual basis[1](index=1&type=chunk)[3](index=3&type=chunk)[11](index=11&type=chunk) [Portfolio Execution](index=1&type=section&id=Portfolio%20Execution) Portfolio execution is driven by strong ARCALYST commercial performance and pipeline advancements for Abiprubart and Mavrilimumab [ARCALYST (rilonacept)](index=1&type=section&id=ARCALYST%20(rilonacept)) ARCALYST generated **$78.9 million** in Q1 2024 revenue, with expanding prescriber base and increasing use in recurrent pericarditis - ARCALYST net product revenue was **$78.9 million** for the first quarter of 2024[5](index=5&type=chunk) - Since its launch in April 2021, approximately **2,000 prescribers** have written ARCALYST prescriptions for recurrent pericarditis[5](index=5&type=chunk) - The average total duration of ARCALYST therapy in recurrent pericarditis was approximately **23 months** as of the end of Q1 2024[5](index=5&type=chunk) - Data from the RESONANCE patient registry presented at ACC.24 shows an increasing proportional use of ARCALYST compared to and in advance of corticosteroids since its commercial availability in 2021[6](index=6&type=chunk) [Abiprubart](index=2&type=section&id=Abiprubart) A Phase 2b trial for Abiprubart in Sjögren's Disease is scheduled to commence in the second half of 2024 - The company expects to initiate a **Phase 2b trial** for **Abiprubart** in patients with **Sjögren's Disease** in **2H 2024**, evaluating biweekly and monthly subcutaneous administration[7](index=7&type=chunk) [Mavrilimumab](index=2&type=section&id=Mavrilimumab) Kiniksa is actively exploring partnership opportunities to advance the development of Mavrilimumab - Kiniksa is evaluating potential partnership opportunities to advance the development of mavrilimumab[8](index=8&type=chunk) [Financial Performance](index=2&type=section&id=Financial%20Performance) Q1 2024 saw total revenue increase to **$79.9 million**, but higher operating expenses led to a **$17.7 million** net loss, while the balance sheet remains strong [Financial Results (Q1 2024)](index=2&type=section&id=Financial%20Results%20(Q1%202024)) Q1 2024 total revenues reached **$79.9 million**, with a net loss of **$17.7 million** and **$213.6 million** in cash and equivalents Statement of Operations (in thousands) | Statement of Operations (in thousands) | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Total Revenue** | **$79,858** | **$48,345** | | Product revenue, net | $78,885 | $42,659 | | **Total Operating Expenses** | **$96,400** | **$59,541** | | Research and development | $26,334 | $15,172 | | Selling, general and administrative | $38,682 | $29,045 | | **Net Loss** | **$(17,704)** | **$(12,270)** | | Net Loss Per Share | $(0.25) | $(0.18) | Balance Sheet Data (in thousands) | Balance Sheet Data (in thousands) | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents, and short-term investments | $213,552 | $206,371 | | Total assets | $519,673 | $526,322 | | Total shareholders' equity | $431,895 | $438,839 | [Financial Guidance (FY 2024)](index=2&type=section&id=Financial%20Guidance%20(FY%202024)) Kiniksa raised its FY 2024 ARCALYST net product revenue guidance to **$370-$390 million** and expects annual cash flow positivity ARCALYST 2024 Net Product Revenue Guidance | Guidance | Previous Range | Updated Range | | :--- | :--- | :--- | | ARCALYST 2024 Net Product Revenue | $360 - $380 million | $370 - $390 million | - Kiniksa expects its current operating plan to remain **cash flow positive** on an annual basis[3](index=3&type=chunk)[11](index=11&type=chunk) [Corporate Information](index=3&type=section&id=Corporate%20Information) This section outlines Kiniksa's business, product portfolio including ARCALYST, Abiprubart, and Mavrilimumab, and forward-looking statement disclaimers [About Kiniksa and its Products](index=3&type=section&id=About%20Kiniksa%20and%20its%20Products) Kiniksa is a commercial-stage biopharmaceutical company developing immune-modulating therapies like ARCALYST, Abiprubart, and Mavrilimumab - Kiniksa is a **commercial-stage biopharmaceutical company** focused on discovering, acquiring, developing, and commercializing therapeutic medicines for debilitating diseases with significant unmet medical need[13](index=13&type=chunk) - **ARCALYST** is a weekly, subcutaneously injected protein that blocks **IL-1α and IL-1β signaling**, approved by the FDA for **recurrent pericarditis, CAPS, and DIRA**[14](index=14&type=chunk) - **Abiprubart** is an investigational monoclonal antibody designed to inhibit the **CD40-CD154 interaction**, a key T-cell co-stimulatory signal critical for B-cell maturation[17](index=17&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) This section includes a disclaimer regarding forward-looking statements, highlighting inherent risks and uncertainties that may affect actual results - The press release contains **forward-looking statements**, including **revenue guidance for ARCALYST**, **clinical trial plans for abiprubart**, and expectations of being **cash flow positive**[19](index=19&type=chunk) - These statements involve **known and unknown risks and uncertainties**, and **actual results may differ materially** The company disclaims any obligation to update these statements[21](index=21&type=chunk)[22](index=22&type=chunk)

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million –– Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KN ...

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon r ...

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 98-1327726 (I.R ...

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice President & Chief Commercial Officer John Paolini - Senior Vice President & Chief Medical Officer Mark Ragosa - Senior Vice President & Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs Operator Good day and thank you ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Incorporation or Organization) Identification No.) Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda (808) 451-3453 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

Financial Performance - ARCALYST net product revenue is expected to be $220-$230 million in 2023, representing approximately 84% growth at the midpoint[7, 25] - Q3 2023 ARCALYST net sales reached $64.8 million, a ~94% year-over-year growth compared to $33.4 million in Q3 2022[9, 32, 46] - The company's cash, cash equivalents, and short-term investments amounted to $201.1 million as of September 30, 2023[7, 31] - The company anticipates its cash reserves will fund the current operating plan into at least 2027[7, 47] ARCALYST Commercial Execution - ARCALYST has achieved >1,450 total prescribers[9] - Repeat prescribers account for approximately 24% of the total prescribers[9] - Payer approval rate for ARCALYST is >90% of completed cases[9] - Patient compliance with ARCALYST therapy is >85%[9] - Only 5% penetration of target recurrent pericarditis population as of YE22[7] KPL-404 Program - KPL-404 is currently in a Phase 2 study and is considered a potentially best-in-class asset[7]